Association Study of 167 Candidate Genes for Schizophrenia Selected by a Multi-Domain Evidence-Based Prioritization Algorithm and Neurodevelopmental Hypothesis

Citation
Zhao, Z., B. T. Webb, P. Jia, T. B. Bigdeli, B. S. Maher, E. van den Oord, S. E. Bergen, et al. 2013. “Association Study of 167 Candidate Genes for Schizophrenia Selected by a Multi-Domain Evidence-Based Prioritization Algorithm and Neurodevelopmental Hypothesis.” PLoS ONE 8 (7): e67776. doi:10.1371/journal.pone.0067776. http://dx.doi.org/10.1371/journal.pone.0067776.

Published Version
doi:10.1371/journal.pone.0067776

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11855903

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Association Study of 167 Candidate Genes for Schizophrenia Selected by a Multi-Domain Evidence-Based Prioritization Algorithm and Neurodevelopmental Hypothesis

Zhongming Zhao1,2,9, Bradley T. Webb3,4, Peilin Jia1, T. Bernard Bigdeli3, Brion S. Maher2, Edwin van den Oord3,4, Sarah E. Bergen6,7, Richard L. AMDUR8, Francis A. O’Neill9, Dermot Walsh10, Dawn L. Thiselton3, Xiangning Chen3,11,12, Carlos N. Pato14, The International Schizophrenia Consortium1, Brien P. Riley3,11,12, Kenneth S. Kendler3,11,12, Ayman H. Fanous3,8,11,13,14.*

1 Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, 2 Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, 3 Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, Virginia, United States of America, 4 Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, Richmond, Virginia, United States of America, 5 Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 6 Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetics Research, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 7 Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America, 8 Washington VA Medical Center, Washington, DC, United States of America, 9 Department of Psychiatry, Queens University, Belfast, United Kingdom, 10 The Health Research Board, Dublin, Ireland, 11 Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States of America, 12 Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, Virginia, United States of America, 13 Department of Psychiatry, Georgetown University School of Medicine, Washington, DC, United States of America, 14 Department of Psychiatry, Keck School of Medicine of the University of Southern California, Los Angeles, California, United States of America.

Abstract

Integrating evidence from multiple domains is useful in prioritizing disease candidate genes for subsequent testing. We ranked all known human genes (n = 3819) under linkage peaks in the Irish Study of High-Density Schizophrenia Families using three different evidence domains: 1) a meta-analysis of microarray gene expression results using the Stanley Brain collection, 2) a schizophrenia protein-protein interaction network, and 3) a systematic literature search. Each gene was assigned a domain-specific p-value and ranked after evaluating the evidence within each domain. For comparison to this ranking process, a large-scale candidate gene hypothesis was also tested by including genes with Gene Ontology terms related to neurodevelopment. Subsequently, genotypes of 3725 SNPs in 167 genes from a custom Illumina iSelect array were used to evaluate the top ranked vs. hypothesis selected genes. Seventy-three genes were both highly ranked and involved in neurodevelopment (category 1) while 42 and 52 genes were exclusive to neurodevelopment (category 2) or highly ranked (category 3), respectively. The most significant associations were observed in genes PRKG1, PRKCE, and CNTN4 but no individual SNPs were significant after correction for multiple testing. Comparison of the approaches showed an excess of significant tests using the hypothesis-driven neurodevelopment category. Random selection of similar sized genes from two independent genome-wide association studies (GWAS) of schizophrenia showed the excess was unlikely by chance. In a further meta-analysis of three GWAS datasets, four candidate SNPs reached nominal significance. Although gene ranking using integrated sources of prior information did not enrich for significant results in the current experiment, gene selection using an a priori hypothesis (neurodevelopment) was superior to random selection. As such, further development of gene ranking strategies using more carefully selected sources of information is warranted.

Citation: Zhao Z, Webb BT, Jia P, Bigdeli TB, Maher BS, et al. (2013) Association Study of 167 Candidate Genes for Schizophrenia Selected by a Multi-Domain Evidence-Based Prioritization Algorithm and Neurodevelopmental Hypothesis. PLoS ONE 8(7): e67776. doi:10.1371/journal.pone.0067776

Editor: Huiping Zhang, Yale University, United States of America

Received August 28, 2012; Accepted May 28, 2013; Published July 29, 2013

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: Two dataset(s) used in the analyses described in this manuscript were obtained from the database of Genotype and Phenotype (dbGaP) found at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number [GAIN: phs000021.v2.p1, nonGAIN: phs00167.v1.p1]. For the GAIN dataset, the genotyping of samples was provided through the Genetic Association Information Network (GAIN). The CATIE trial was funded by a grant from the National Institute of Mental Health (N01 MH90001) along with MH074027 (PI PF Sullivan). Genotyping was funded by Eli Lilly and Company. The CATIE dataset was approved to use in this analysis through the authors’ application. This work was supported by Department of Veterans Affairs Merit Review Program (101CX000278, to AHF), 2009 NARSAD Malitz Investigator Award (to ZJ) and 2010 NARSAD Young Investigator Award (to PJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Genotyping was funded by Eli Lilly and Company. The CATIE dataset was approved to use in this analysis through the authors’ application. These genotypes are available online and made available to qualified investigators. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: ayman.fanous@va.gov

† These authors contributed equally to this work.

†† Membership of The International Schizophrenia Consortium is provided in the Acknowledgments.
Introduction

A wealth of information relevant to the genetics of complex disorders is available via a wide variety of platforms such as gene expression, protein–protein interactions (PPIs), biological pathways, and Gene Ontology (GO). It was hoped that the advent of large scale genome-wide association studies (GWAS) would eliminate the need to utilize this data as a means to uncover susceptibility loci. However, psychiatric GWAS have shown that there are likely many loci of small effect and few results are significant after corrections for multiple testing [1,2,3]. Furthermore, the loci that do survive only account for modest proportions of heritability. Therefore, novel methods are still needed to identify additional causative loci.

Schizophrenia is a disorder that is particularly suitable to this type of approach. While other complex disorders and traits such as type 2 diabetes and height have been gathering a rapidly growing list of replicated and validated susceptibility loci, several features of schizophrenia will arguably make such success less likely. Although its heritability is higher than many complex disorders such as type 2 diabetes, its prevalence is lower. This makes very large studies with tens or hundreds of thousands of participants much more challenging (albeit necessary in order to detect an effect). There is also phenotypic and diagnostic heterogeneity which is arguably less present in other complex disorders and which may reflect genetic heterogeneity as well. Moreover, for schizophrenia, there is increasing evidence suggesting a complex genetic architecture comprising a mixture of rare highly-penetrant mutations such as large deletions in gene NRXN1 [4] as well as common single nucleotide polymorphisms (SNPs) [5]. Furthermore, well developed animal models or the availability of patient tissue are very limited. However, there are multiple schizophrenia GWAS available now, which can be used to evaluate hypotheses or ranking procedures.

We have previously developed a procedure for gene ranking based on a priori evidence and the results from a small validation study were encouraging [6]. Here, we report a modified ranking procedure for complex diseases such as schizophrenia, applied it to all genes residing in regions of linkage in the Irish Study of High Density Schizophrenia Families (ISHDSF) sample, and performed a larger evaluation of the method. To evaluate the utility of this approach, we compared it with a gene selection approach based on the well-established neurodevelopmental etiological hypothesis of schizophrenia [7].

Materials and Methods

Ethics statement

This research was approved by the Institutional Review Boards of Virginia Commonwealth University School of Medicine and the Washington VA Medical Center. All subjects gave verbal assent to participate in research, as this represented the ethical standard in Ireland at the time these data were collected. This strategy was specifically approved by the Health Research Board, Dublin. Permission was received to use the data in this study, and the data we de-identified prior to analysis.

Subjects and phenotypes

The Irish Study of High Density Schizophrenia Families (ISHDSF) sample consists of 265 high-density schizophrenia families with 1408 individuals available for genotyping [8]. All participating individuals gave appropriate informed consent to the study. The sample was divided into 4 concentric diagnostic categories for analysis purposes, ranging from core schizophrenia (D2, 625 affected individuals), through narrow spectrum (‘intermediate phenotype’ D5, 804 affected individuals), broad (D6, 888 affected individuals) and very broad spectrum disease (D9, 1172 affected individuals). Phenotypic details of these subcategories are given briefly in Thiselton et al. [9].

Linkage regions

We first limited the ranking to genes in regions with evidence for linkage in the ISHDSF. These regions were obtained from an autosomal genome-wide scan using over 4000 SNPs as part of the Multicenter Genetic Studies of Schizophrenia (PI, Douglas F. Levinson, MD) [10]. Regions were defined as genomic segments with nonparametric linkage (NPL) maximum score of at least 2.0 and telomeric and centromeric boundaries of NPLs of 1.0. The detailed genomic locations were provided in File S1. A bioinformatics search of these regions yielded 3819 human protein-coding genes.

Prior sources of information

For each of the 3819 genes, we obtained a separate p-value pertaining to each of 3 domains: 1) gene expression, 2) protein–protein interaction (PPI) subnetwork, and 3) high-throughput literature search, as illustrated in Figure 1. First, the p-value for fold-change in each gene’s expression level was obtained from the Stanley Brain Expression Database (http://www.stanleygenomics.org), which contains meta-analysis results using data from 12 different studies and 988 arrays. A False Discovery Rate (FDR) procedure [11] was applied to the uncorrected p-values and used to generate a corrected ranked p-value. Second, assuming disease genes may be functionally connected, we identified the genes whose proteins interact closely with proteins encoded by three established schizophrenia susceptibility genes (DTNBP1 [12,13], NRG1 [14,15], and AKT1 [9]) in the PPI network. A comprehensive human PPI network was generated using human PPI data retrieved from NCBI Entrez Gene (February 2007) which summarizes interactions from multiple sources including HPRD (http://www.hprd.org) [16], BioGrid (http://www.thebiogrid.org) [17,18], and BIND (http://www.bind.ca) [19]. After removing redundant and problematic interactions, 52,288 unique human PPI pairs remained in the network. The program Pajek (http://vlado.fmf.uni-lj.si/pub/networks/pajek/) [20] was used to determine the minimum number of steps between the proteins encoded by DTNBP1, NRG1, and AKT1 and every other human gene in the PPI network. Each of the 3819 genes was assigned a rank based p-value based on the number of steps (lowest to highest). The hypothesis is that a gene closer in the network to a probable susceptibility gene is more likely to harbor susceptibility alleles. Finally, high-throughput literature searching was performed using a Perl script which automatically queried the PubMed database (http://www.ncbi.nlm.nih.gov/pubmed/) for each of the 3819 genes along with 29 schizophrenia-related search terms that we assembled (3819×29=110,751 searches). These search terms were divided into several categories: disease states (e.g., “schizophrenia”, “psychosis”), neurotransmitters (e.g., glutamate, dopamine), neuronal features (e.g., “dendrite”, “axon”), brain development, and brain structures (e.g., “cortex”). Genes were ranked...
According to the number of categories which yielded positive "hits", and assigned a ranked p-value.

**Ranking and gene selection**

For a final ranking of these genes, we summed the $-\log_{10}$ of their p-values on each of the three domains (gene expression, PPI network, and literature search). Two subsets of the 3819 genes were selected for tag-based SNP genotyping and association analysis (see Figure 1). The first set was based on the commonly accepted neurodevelopmental hypothesis of schizophrenia ("hypothesis-based") [7,21,22], where all genes with GO terms that included "nervous system development" or "brain development" were selected. The second set was rank-based and included as many top ranked genes as could be included on the custom array based on the remaining unallocated SNPs. In practice, many of the top ranked genes had already been selected by the hypothesis procedure and were in the first set. This led to 125 of the 151 top ranked genes having already been selected for genotyping with 52 being exclusively highly ranked without being implicated in neurodevelopment. In summary, among the 167 genes we selected for genotyping, 73 were both highly ranked and involved in neurodevelopment (category 1), while 42 and 52 genes were exclusive to neurodevelopment (category 2) or highly ranked without being implicated in neurode-velopment (category 3), respectively.

**SNP selection and genotyping**

We then identified the genomic region of each candidate gene based on gene annotation information in the UCSC Genome Browser (UCSC hg17/NCBI Build 35, http://genome.ucsc.edu/).

For the genomic regions, we attempted to select all haplotype-tagging genetic SNPs within each gene using computer program Tagger [23] ($r^2 = 0.8$, minor allele frequency (MAF) = 0.1) and the HapMap data (phase 2, http://hapmap.ncbi.nlm.nih.gov/). Genotyping was conducted by Illumina, Inc. using a custom iSelect array, which employs the Infinium assay. In total, genomic DNA for 1128 individuals was submitted for genotyping. Average genotyping completion rate across all SNPs was 99.97%. Of 1128 samples, 21 failed to yield usable genotypes. Genotypes were examined for apparent Mendelian incompatibilities using PED-CHECK v1.1 [24] and removed for entire families where appropriate. After excluding SNPs failing quality control, 3725 SNPs were available for analysis.

**Association analyses**

Association analysis for categorical diagnoses of schizophrenia was performed using PDTPHASE. (UNPHASED v.2,4,04), an implementation of the pedigree disequilibrium test (PDT) with extensions to deal with uncertain haplotypes and missing data [25,26]. The PDT is an extension of the transmission disequilibrium test (TDT) to examine general pedigree structures and is similarly a test of association in the presence of linkage.

**GWAS datasets**

The International Schizophrenia Consortium (ISC) samples were collected from eight study sites in Europe and the US [1]. The samples were genotyped using Affymetrix Genome-Wide Human SNP 5.0 and 6.0 arrays. This data was initially analyzed by ISC [1] and was used here for evaluation. A total of 3322 patients with schizophrenia, 3587 normal controls of European ancestry, and a total of 739,995 SNPs were included in our analysis. To account for potential population sub-structure associated with collection sites, the Cochran-Mantel-Haenszel test was used for a single marker association test [1].

We used two GWAS datasets from the Molecular Genetics of Schizophrenia (MGS): The Genetic Association Information Network (GAIN) dataset for schizophrenia and nonGAIN. The GAIN dataset was genotyped using Affymetrix Genome-Wide Human SNP 6.0 array. Our access to this dataset was approved by the GAIN Data Access Committee (DAC request #4532-2) through the NCBI dbGaP. For optimal comparison with the Irish samples (ISHDSF) genotyped in this study, we used only the GAIN samples of European ancestry. We performed quality control (QC) as follows. For individuals, those with a high missing genotype rate (>5%), extreme heterozygosity rate (±3 s.d. from the mean value of the distribution), or problematic gender assignment were excluded. PLINK [27] was used to compute the identify-by-state (IBS) matrix to pinpoint duplicate or cryptic relationships between individuals. We retained the sample with the highest call rate for each pair of samples with an identity-by-descent (IBD) being greater than 0.185. Principle component analysis (PCA) was performed using the smartpca program in EIGENSTRAT [28] to detect population structure and to allow removal of outlier individuals. Eight significant PCs with the Tracy Widom test p-value<0.05 were used as covariates for logistic regression (additive model). For genotyped SNPs, those with a missing genotype rate >5%, MAF <0.05, or departing from Hardy-Weinberg equilibrium (p<1×10−6) were removed. The final analytic dataset included 1158 schizophrenia cases and 1377 controls and a total of 654,271 SNPs. The genomic inflation factor (λ), which was defined as the ratio of the median of the empirically observed distribution of the test statistic to the expected median and an indication of the extent of excess false positive rate [29], was 1.04. This value indicates little (if any) inflation.
The MGS - nonGAIN dataset was genotyped in the same laboratory as the MGS-GAIN, but in different phases. Access to this dataset was approved by dbGaP (DAC request #4533-3). Similar QC and PCA processes were performed as described for GAIN. These processes retained 1086 cases and 1268 controls and 623,059 SNPs for subsequent analyses. Fifteen significant PCs with the Tracy-Widom test p-value < 0.05 were used as covariates for logistic regression (additive model) using PLINK. The genomic inflation factor \( \lambda \) was 1.04.

CATIE. (Clinical Antipsychotic Trials of Intervention Effectiveness) is a multi-phase randomized controlled trial of antipsychotic medications involving 1460 persons with schizophrenia. CATIE GWAS included 492,900 SNPs genotyped in a total of 738 cases and 733 group-matched controls using the Affymetrix 500K two-chip genotyping platform plus a custom 164K fill-in chip [30]. Access to this dataset was approved by the National Institute of Mental Health (NIMH) Schizophrenia Genetics Initiative.

**Imputation and meta-analysis**

The three GWAS datasets, ISC, GAIN, and nonGAIN, were genotyped on the same Affymetrix platform. To make the data from these GWAS datasets comparable with our custom-design SNPs, we conducted imputation analysis using the HapMap genotyping data for CEU population (release 24) as reference panel. We predicted the genotyping data for a total of 66 SNPs involved in 22 genes using the tool `impute2` [31]. Frequentist association test was then conducted for SNP association using the tool `snpptest` [32] by the option “-frequentist 1”, and a missing data likelihood score test for the imputed genotypes by the option “-method score”.

We conducted meta-analysis of candidate SNPs using the imputed data. We performed inverse-variance weighted meta-analysis based on the fixed-effects model using the tool `meta` (http://www.stats.ox.ac.uk/~jlsiu/meta.html). This method combines study-specific betas values under the fixed-effects model using the inverse of the corresponding standard errors as weights. Between-study heterogeneity was tested based on \( I^2 \) and Q statistics. SNPs having possible evidence of heterogeneity \( (I^2 < 0.05) \) were removed.

**Gene set simulations**

In order to determine how often the observed enrichment in p-values would occur, 100,000 simulations were performed where the same number of genes was randomly chosen from the CATIE and GAIN GWAS results. Then, p-values less than 0.05 and 0.005 for genotyped SNPs that mapped to the randomly chosen genes were counted. Due to the great variation in gene size, SNP density per gene, and difference in arrays used in each GWAS, the number of SNPs in each iteration of the simulations could vary. Therefore, we examined whether the observed number of SNPs for the real set of ranked genes was similar to randomly selected sets. The empirical significance for SNP count, minimum p-value, and p-values below a given threshold were calculated both using all simulations and restricted to those simulations where the SNP count was not significantly different from observed. The empirical significance was calculated using the number of simulations greater than or equal to the observed plus one divided by the total number of simulations as per North et al. [33].

**Results**

Figure 1 summarizes the data process, algorithm for gene ranking and selection, custom-based genotyping and association analysis. We analyzed 3725 SNPs covering 167 prioritized genes whose genotypes were examined in 1107 individuals from the 265 high-density schizophrenia families using a custom Illumina iSelect array. This gene list included 115 genes selected by neurodevelopmental hypothesis and 123 genes selected by gene ranking algorithm – 73 were common between these two selection categories (see Materials and Methods). The minimum p-value among these 3725 tested SNPs was 0.000536 in gene PRKCE (SNP rs1904687). This gene was chosen as part of the neurodevelopmental hypothesis and highly rank categories. Table 1 shows the genes with at least one significant SNP.

| Gene  | Category | Rank | # SNPs | Min p-value |
|-------|----------|------|--------|-------------|
| PRKCE | 1        | 35   | 229    | 0.001321    |
| CNTN4 | 2        | 645  | 381    | 0.001474    |
| ENOX1 | 2        | 549  | 2      | 0.001949    |
| INSX1 | 1        | 109  | 51     | 0.001975    |
| IKBKB | 3        | 88   | 2      | 0.001978    |
| VAV3  | 3        | 98   | 76     | 0.002273    |
| UTRN  | 3        | 99   | 56     | 0.002886    |
| SH3GL2| 2        | 538  | 74     | 0.003219    |
| NPAS2 | 3        | 96   | 55     | 0.003419    |
| IL19  | 3        | 149  | 8      | 0.003559    |
| EGFR  | 3        | 8    | 67     | 0.004041    |
| NRP1  | 2        | 291  | 56     | 0.004202    |
| HLA-DRA| 2       | 144  | 11     | 0.004317    |
| MAL   | 2        | 361  | 4      | 0.004592    |
| CNTN6 | 2        | 862  | 146    | 0.005419    |
| VAV2  | 1        | 132  | 66     | 0.006312    |
| PPP2R2B| 3       | 151  | 47     | 0.007685    |
| IKKX  | 1        | 65   | 4      | 0.008221    |
| MGMT  | 3        | 78   | 52     | 0.008672    |
| NOTCH1| 2        | 439  | 15     | 0.009058    |
| GRIA1 | 3        | 101  | 67     | 0.009817    |

Table 1. Summary of genes with at least one significant (p<0.01) SNP.
performed worse than randomly selected genes. A summary of the number of genes, SNPs, and p-values by category is provided in Table 2.

Comparison with published schizophrenia GWAS results

We compared the current results to two published schizophrenia GWAS datasets, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) GWAS dataset [30] and the GAIN dataset from Molecular Genetics of Schizophrenia (MGS) [2] (see Materials and Methods). Simulated gene selection was used to determine how often the observed enrichment would occur if the whole genome was assessed. Lists of genes were randomly selected 100,000 times using the same numbers of genes selected in the three selection categories (73, 42, and 52 for categories 1, 2, and 3, respectively). Unfiltered simulation showed that the number of SNPs per gene in the current study was significantly higher than for randomly selected genes from either the CATIE or GAIN study. Therefore, the tests for significant enrichment of p-values below 0.05 and 0.005 are biased in the unfiltered simulations. To reduce the bias, random gene sets were ranked based on the total number of SNPs. Different rank filtering thresholds were tested until there was no significant difference in total number of SNPs between the observed and simulated sets. The rank filter thresholds necessary to achieve non-significance were quite different for the CATIE and GAIN studies with the top 500 and 10,000 being used respectively. The filtered simulations showed the ‘neurodevelopment only’ category to be significantly different (p = 0.012) and marginally (p = 0.058) enriched for p-values less than 0.005 in the CATIE and MGS-GAIN samples, respectively. Further details of the simulation results are in Table 3.

Meta-analysis

In our SNP list, there were 66 SNPs with p < 0.01. These SNPs belonged to 22 genes. We examined them in a meta-analysis using three schizophrenia GWAS datasets (ISC, GAIN and nonGAIN). Using the inverse-variance weighted meta-analysis method, we identified 3 SNPs in 3 genes that showed nominal significance (p < 0.05) (Table 4). None of them had significant heterogeneity by heterogeneity test. These SNPs are rs2176348 in PRKCE (p-value = 0.042), rs552551 in MGMT (p-value = 0.044), and rs2616591 in CNTN4 (p-value = 0.048). Another SNP, rs2043534 in MGMT, had marginal significance (p-value = 0.062). However, none of these SNPs passed Bonferroni multiple testing correction.

We further examined the association signals of these SNPs using the data from the Psychiatric Genomics Consortium (PGC), the largest and most comprehensive cohort dataset for schizophrenia association studies so far [34]. Among the 66 SNPs, 24 were not available in the public release of the PGC dataset (https://pgc.unc.edu/Sharing.php); thus, they could not be imputed due to the lack of access to PGC’s raw genotyping data. For the 42 SNPs that had p-values in the PGC dataset, we found that three were nominally significant (p < 0.05), including one SNP (rs2616591) in Table 4. Of note, for the four SNPs that were significant or marginally significant in the meta-analysis of our SNPs (Table 4), two were available in the PGC dataset including SNP rs2616591 that had a small p value (1.68×10⁻⁷).

Discussion

In this study, we attempted to develop gene ranking strategies based on either evidence from multiple domains (meta-analysis of gene expression, proteins closely interacting with well-studied schizophrenia susceptibility genes, and a systematic literature search) or the neurodevelopmental hypothesis and then applied them to the genes under linkage peaks in the Irish Study of High-Density Schizophrenia Families. For the top ranked genes, we tested their associations with schizophrenia using a custom Illumina iSelect array. The association signals were further evaluated using three GWAS datasets (ISC, GAIN, and non-GAIN). Although none of the SNPs were robustly associated, clusters of significant SNPs were found in several large genes including PRKGI, CNTN4, and PRKCE. These genes were tested not due to rank but as part of the neurodevelopmental hypothesis. This category showed enrichment for significant association signals, and simulations showed this enrichment is unlikely to be due to chance.

There is additional evidence that makes the top results of interest in addition to the reason they were originally tested. CNTN4 (contactin 4) is a neural cell adhesion molecule whose gene has been reported to be associated with autism and developmental delay in multiple studies [35,36,37]. Interestingly, another member of the contactin family, CNTNAP2, has been found to be associated with both schizophrenia and autism [38]. PRKGI and PRKCE are known as protein kinase cGMP-dependent, type I and protein kinase C epsilon, respectively. Although they are both protein kinases, they are functionally distinct and activated via different mechanisms. PRKGI is dependent on cyclic GMP for activation while PRKCE is activated by calcium and the second messenger diacylglycerol. PRKGI has previously shown its association with schizophrenia with the 21st most significant SNP in the CATIE GWAS [30]. PRKGI also interacts with RGS2 and GABBR1, which have

| Category | # genes | # SNPs | Highly ranked Neuro-development | Mean p-value | SNPs with p<0.05 Obs. Exp. | SNPs with p<0.005 Obs. Exp. |
|----------|---------|--------|---------------------------------|-------------|---------------------------|-----------------------------|
| 1        | 73      | 1271   | Yes                             | 0.521       | 42                         | 63.6                        |
| 2        | 42      | 1525   | No                              | 0.480       | 103                        | 63.6                        |
| 3        | 52      | 929    | Yes                             | 0.488       | 63                         | 46.5                        |
| 1+2      | 115     | 2796   | -                               | 0.498       | 145                        | 139.8                       |
| 1+3      | 125     | 2200   | Yes                             | 0.507       | 105                        | 110.0                       |
| All      | 167     | 3725   |                                 |             | 208                        | 186.3                       |

Category 1: genes are both highly ranked and involved in neurodevelopment. Category 2: genes are exclusive to neurodevelopment. Category 3: genes are exclusively highly ranked (see details in Materials and Methods).

doi:10.1371/journal.pone.0067776.t002

Table 2. Summary of genes and number of SNPs per test category.
shown modest association with schizophrenia symptoms [39] and schizoaffective disorder [40], respectively. Finally, PRKG1 can attenuate beta-catenin expression [41], which is a known downstream target of antipsychotics [42]. PRKCE interacts with several proteins encoded by genes of potential relevance to psychiatric disorders, including the glutamate decarboxylases (GAD1, GAD2), NMDA receptors (GRIN2D, GRIN1), and a metabotropic glutamate receptor (GRM5). PRKCE is also activated by the stimulation of nicotinic receptors [43]. Although these genes were not highly ranked, prior evidence makes them all plausible candidates for schizophrenia. Therefore, each could be chosen using expanded sources of prior information and a refined ranking procedure.

There are several limitations to the current work that could be potentially improved in future application. First, the primary filtering of genes in the genome was done using linkage results from the ISHDSF. Due to the large number of risk variants in schizophrenia, there are likely to be many true associations outside of these regions. The second limitation is the small number of genes and minimum step approach used for the PPI network sets. We used three well-studied genes (DTNBP1, NRG1, and AKT1) in this work. More informative genes including microRNA genes (e.g., miR-137 [34,44] and TCF4 [3,34]) were recently reported to be associated with schizophrenia and could improve this approach. Larger networks or results from more comprehensive network analyses are probably superior; nevertheless, this work proves the concept using more closely related genes in the PPI network.

Table 3. Comparison of ISHDSF rank and hypothesis based gene selection results to random gene selection in schizophrenia CATIE and GAIN GWAS datasets.

| Category | Simulation Method | Observed in ISHDSF | CATIE GWAS | Gain GWAS |
|----------|-------------------|--------------------|------------|-----------|
|          |                   |                    | 100,000<sup>4</sup> | Top 500<sup>4</sup> | 100,000<sup>4</sup> | Top 10,000<sup>4</sup> | Top 500<sup>4</sup> |
| All      | SNP count         | 3741               | 0.0097     | 0.194     | 0.066     | 0.659     | 0.998     |
|          | min p-value       | 0.000582           | 0.618      | 0.896     | 0.787     | 0.879     | 0.964     |
|          | # SNPs with p<0.05 | 208                | 0.0019     | 0.208     | 0.158     | 0.767     | 1         |
|          | # SNPs with p<0.005| 23                 | 0.0258     | 0.234     | 0.241     | 0.614     | 0.924     |
| 1        | SNP count         | 1271               | 0.079      | 0.855     | 0.389     | 0.806     | 0.892     |
|          | min p             | 0.001975           | 0.729      | 0.872     | 0.859     | 0.920     | 0.956     |
|          | # SNPs with p<0.05 | 42                 | 0.586      | 0.914     | 0.887     | 0.976     | 0.986     |
|          | # SNPs with p<0.005| 4                  | 0.556      | 0.836     | 0.780     | 0.895     | 0.934     |
| 2        | SNP count         | 1525               | 0.0022     | 0.104     | 0.017     | 0.121     | 0.267     |
|          | min p             | 0.000582           | 0.214      | 0.349     | 0.319     | 0.398     | 0.445     |
|          | # SNPs with p<0.05 | 103                | 0.00042    | 0.032     | 0.017     | 0.102     | 0.232     |
|          | # SNPs with p<0.005| 17                 | 0.00294    | 0.012     | 0.018     | 0.058     | 0.142     |
| 3        | SNP count         | 929                | 0.088      | 0.591     | 0.358     | 0.707     | 0.822     |
|          | min p             | 0.003559           | 0.797      | 0.926     | 0.883     | 0.932     | 0.972     |
|          | # SNPs with p<0.05 | 63                 | 0.049      | 0.427     | 0.264     | 0.558     | 0.719     |
|          | # SNPs with p<0.005| 2                  | 0.701      | 0.896     | 0.837     | 0.914     | 0.954     |

*Category 1: genes are both highly ranked and involved in neurodevelopment. Category 2: genes are exclusive to neurodevelopment. Category 3: genes are exclusively highly ranked (see details in text).

*We performed simulations by four methods: 1) based on the count of SNPs, 2) based on the minimum p-value, 3) based on the number of SNPs with p<0.05, and 4) based on the number of SNPs with p<0.005.

*100,000 simulations (see text).

*To reduce bias, simulations were filtered with top 500 or 10,000 SNPs being used (see Materials and Methods).

doi:10.1371/journal.pone.0067776.t003

Table 4. Four SNPs from the meta-analysis of 66 SNPs using GAIN, nonGAIN, and ISC GWAS datasets.

| Gene  | SNP ID     | Chr. | Position (bp) | Allele | Meta-analysis p-value | Beta     | s.e. | Phetetogeneity | I² | PGAIN | PnonGAIN | PISC | IHDS min p  |
|-------|------------|------|---------------|--------|------------------------|----------|------|----------------|----|-------|----------|------|-------------|
| PRKCE | rs2176348  | 2    | 45798033      | A/G    | 0.044                  | -0.064   | 0.032| 0.838          |    | 0.470 | 0.599    | 0.057| 0.004       |
| MGMT  | rs52551    | 10   | 131271915     | C/T    | 0.044                  | 0.073    | 0.036| 0.29           | 19.15| 0.996 | 0.797    | 0.011| 0.009       |
| CNTN4 | rs2616591  | 3    | 2614861       | C/T    | 0.048                  | 0.088    | 0.044| 0.481          |    | 0.347 | 0.061    | NA   | 0.004       |
| NPAS2 | rs2043534  | 2    | 100847317     | C/T    | 0.062                  | 0.064    | 0.035| 0.635          |    | 0.258 | 0.808    | 0.081| 0.003       |

Chr.: chromosome. GAIN, nonGAIN and ISC are three GWAS datasets for meta-analysis. ISHDSF min p was the smallest p-value in the gene from the IHDS dataset (this study). NA: this SNP was not analyzed in ISC due to missing genotyping data in samples.

doi:10.1371/journal.pone.0067776.t004
network. Third, while our keyword-based literature search seemed to be useful, it might include underpowered studies, negative findings, or studies with methodological flaws or reported false positive results. This is a common problem in literature mining, which could be improved by careful manual check or advanced literature mining technologies like natural language processing (NLP). In our study, gene ranking was performed by the combined evidence from three domains (gene expression meta-analysis, PPI subnetwork, and literature mining). This strategy might help reduce the noisy data from literature mining. Finally, besides the well-supported neurodevelopmental hypothesis, we may test other hypotheses or the candidate genes for samples with refined characterization of phenotypic spectrum. For example, Greenewood et al. [45] recently tested a set of schizophrenia candidate genes in schizophrenia-related endophenotypes, suggesting both converging and independent genetic pathways mediating schizophrenia risk and pathogenesis.

There are several ways to improve or expand the gene selection and prioritization approaches. First, we may develop a more comprehensive data integration approach. This includes the integration of data from multiple domains such as gene expression, copy number variation (CNV), methylation, microRNA, association results, etc. This has been demonstrated in our weight matrix approach for evidence scores [46], as well as other approaches like convergent analysis [47,48,49] and microRNA regulatory network analysis [50]. Of note, TCP4 gene, along with three other genes reported in the PGC meta-analysis (CACNA1C, C10orf26, and Carvalho, 13 Christopher Morley, 21 Ayman Fanous, 13,22,23,24 David Milanova, 26 Michael J Owen 21 Karolinska Institutet/University of North Carolina at Chapel Hill School of Medicine: Roy, Elena Nolte,23,24 and Caroline Crombie,15 Gillian Fraser,15 Soh Leh Kuan,15 Nicholas Walker,20 David St Clair,14 University of Edinburgh: Douglas HR Blackwood,10 Walter J Muir,10 Kevin A McGhee,10 Ben Pickard,10 Pat Malloy,10 Alan W Maclean,10 Margaret Van Beck,10 Queensland Institute of Medical Research: Naomi R Wray,5 Stuart Macgregor,5 Peter M Visscher,2 University of Southern California: Michelle T. Pato,13 Helen C. Blangero,13,25 Nicholas Carvalho,13 Christopher Morley,21 Ayman Fanous,14,22,23,24 David Conti,13 James A Knowles,13 Carlos Paz Ferreira,25 Antonio Macedo,26 M Helena Azevedo,26 Carlos N Pato,13 Massachusetts General Hospital: Jennifer L. Stone,13,24,4 Douglas M Rudfer,13,24,4 Andrew N Kirby,13,24,4 Manuel AR Ferreira,13,24,4,5 Mark J Daly,13,24,5 Shaun M Purcell,13,24,5 Pamela Sklar,24,13,24 Stanley Center for Psychiatric Research and Broad Institute of MIT and Harvard: Vincent Pickrell,13,24,5 Jennifer L Stone,13,24,5 Kimberly Chambert,13,24,5 Douglas M Rudfer,13,24,5 Finny Kuruvilla,4 Stacey B Gabriel,4 Kristin Ardlie,4 Jennifer L Moran,4 Mark J Daly,13,24,5 Edward M Scolnick,3,4 Pamela Sklar,13,24,5

1Psychiatric and Neurodevelopmental Genetics Unit, 2Center for Human Genetic Research, Massachusetts General Hospital, 185 Cambridge Street, Boston, Massachusetts 02114, USA. 3Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA. 4The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA. 5Queensland Institute of Medical Research, 300 Herston Road, Brisbane, Queensland 4006, Australia. 6MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine, School of Medicine, Cardiff University, Cardiff C14 4XY, UK. 7Departments of Genetics, Psychiatry, and Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. 8Molecular Psychiatry Laboratory, Research Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, 46 Cleveland Street, LondonW1T3JF, UK. 9NeuropsychiatricGenetics Research Group, Department of Psychiatry and Institute of Molecular Medicine, Trinity College Dublin, Dublin 2, Ireland. 10Division of Psychiatry, University of Oxford, Royal Edinburgh Hospital, Edinburgh EH10 5HF, UK. 11Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77 Stockholm, Sweden. 12Department of Neuroscience, Psychiatry, Ullera’ker, Uppsala University, SE-750 17 Uppsala, Sweden. 13Center for Genomic Psychiatry, University of Southern California, Los Angeles, California 90033, USA. 14Institute of Medical Sciences, 15Department of Mental Health, University of Aberdeen, Aberdeen AB25 2ZD, UK. 16Department of Medical Genetics, University Hospital Mälardom, Sofia 1431, Bulgaria. 17Department of Psychiatry, First Psychiatric Clinic, Alexander University Hospital, Sofia 1431, Bulgaria. 18West Berkshire NHS Trust, 25 Erleigh Road, Reading RG3 5LR, UK. 19Department of Psychiatry, University of Oxford, Wnarford Hospital, Headington, Oxford OX3 7JX, UK. 20Ravenscraig Hospital, Inverkip Road, Greenock PA16 9HA, UK. 21State University of

Supporting Information

File S1 This file includes 26 linkage peaks (genomic regions) with nonparametric linkage (NPL) maximum score being at least 2 and telomeric and centromeric boundaries of NPLs of 1.0. (XLS)

File S2 This file includes details of the 167 genes ranked by three categories and their SNPs with association results in The Irish Study of High Density Schizophrenia Families (ISHDSF) samples. (XLSX)

Acknowledgments

Two dataset(s) used in the analyses described in this manuscript were obtained from the database of Genotype and Phenotype (dbGaP) found at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number [GAIN: phs000012.v2.p1, nonGAIN: phs001676.v1.p1]. For the GAIN dataset, the genotyping of samples was provided through the Genetic Association Information Network (GAIN). The CATIE dataset was approved to use in this analysis through our application. We thank the Schizophrenia Psychiatric Genomics Consortium (PGC) for sharing the meta-analysis results. We thank the families for their participation in this research.

The members of the International schizophrenia consortium:

Cardiff University: Michael C O'Donovan,2 George K Kiou,7 Nick J Craddock,2 Peter A Holmans,3 Nigel M Williams,3 Lynnhila Georgieva,1 Ivan Nikolos,6 N Norton,6 H Williams,6 Draga Toncheva,6 Vilma Milanova,2 Michael J Owen 21 Karolinska Institutet/University of North Carolina at Chapel Hill School of Medicine: Roy, Elena Nolte,23,24 and Caroline Crombie,15 Gillian Fraser,15 Soh Leh Kuan,15 Nicholas Walker,20 David St Clair,14 University of Edinburgh: Douglas HR Blackwood,10 Walter J Muir,10 Kevin A McGhee,10 Ben Pickard,10 Pat Malloy,10 Alan W Maclean,10 Margaret Van Beck,10 Queensland Institute of Medical Research: Naomi R Wray,5 Stuart Macgregor,5 Peter M Visscher,2 University of Southern California: Michelle T. Pato,13 Helen C. Blangero,13,25 Nicholas Carvalho,13 Christopher Morley,21 Ayman Fanous,14,22,23,24 David Conti,13 James A Knowles,13 Carlos Paz Ferreira,25 Antonio Macedo,26 M Helena Azevedo,26 Carlos N Pato,13 Massachusetts General Hospital: Jennifer L. Stone,13,24,4 Douglas M Rudfer,13,24,4 Andrew N Kirby,13,24,4 Manuel AR Ferreira,13,24,4,5 Mark J Daly,13,24,5 Shaun M Purcell,13,24,5 Pamela Sklar,24,13,24 Stanley Center for Psychiatric Research and Broad Institute of MIT and Harvard: Vincent Pickrell,13,24,5 Jennifer L Stone,13,24,5 Kimberly Chambert,13,24,5 Douglas M Rudfer,13,24,5 Finny Kuruvilla,4 Stacey B Gabriel,4 Kristin Ardlie,4 Jennifer L Moran,4 Mark J Daly,13,24,5 Edward M Scolnick,3,4 Pamela Sklar,13,24,5

1Psychiatric and Neurodevelopmental Genetics Unit, 2Center for Human Genetic Research, Massachusetts General Hospital, 185 Cambridge Street, Boston, Massachusetts 02114, USA. 3Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA. 4The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA. 5Queensland Institute of Medical Research, 300 Herston Road, Brisbane, Queensland 4006, Australia. 6MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine, School of Medicine, Cardiff University, Cardiff C14 4XY, UK. 7Departments of Genetics, Psychiatry, and Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. 8Molecular Psychiatry Laboratory, Research Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, 46 Cleveland Street, LondonW1T3JF, UK. 9NeuropsychiatricGenetics Research Group, Department of Psychiatry and Institute of Molecular Medicine, Trinity College Dublin, Dublin 2, Ireland. 10Division of Psychiatry, University of Oxford, Royal Edinburgh Hospital, Edinburgh EH10 5HF, UK. 11Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77 Stockholm, Sweden. 12Department of Neuroscience, Psychiatry, Ullera’ker, Uppsala University, SE-750 17 Uppsala, Sweden. 13Center for Genomic Psychiatry, University of Southern California, Los Angeles, California 90033, USA. 14Institute of Medical Sciences, 15Department of Mental Health, University of Aberdeen, Aberdeen AB25 2ZD, UK. 16Department of Medical Genetics, University Hospital Mälardom, Sofia 1431, Bulgaria. 17Department of Psychiatry, First Psychiatric Clinic, Alexander University Hospital, Sofia 1431, Bulgaria. 18West Berkshire NHS Trust, 25 Erleigh Road, Reading RG3 5LR, UK. 19Department of Psychiatry, University of Oxford, Warnford Hospital, Headington, Oxford OX3 7JX, UK. 20Ravenscraig Hospital, Inverkip Road, Greenock PA16 9HA, UK. 21State University of

PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e67776
New York – Upstate Medical University, Syracuse, New York 13210, USA. 2Department of Psychiatry, Georgetown University School of Medicine, Washington DC 20057, USA. 2Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia 23298, USA. 2Department of Psychiatry, Sao Miguel, 9500-510 Azores, Portugal. 2Department of Psychiatry University of Coimbra, 3004-504 Coimbra, Portugal.

References

1. Purcell SM, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.

2. Webb BT, Sullivan PF, Skelly T, van den Oord EJ (2008) Model-based gene and schizophrenia: a meta-analysis showing strong positive association of neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 15: 1995–2003.

3. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, et al. (2009) Common variants conferring risk of schizophrenia. Nature 460: 753–757.

4. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT (2006) Recent advances in the neurobiology of schizophrenia. Mol Interv 3: 27–39.

5. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, et al. (2011) Genome-wide association study identifies five new schizophrenia loci. Nat Genet 43: 909–976.

6. Martin ER, Monks SA, Warren LL, Kaplan NL (2000) A test for linkage and genotype incompatibilities in linkage analysis. Am J Hum Genet 63: 259–266.

7. Martin ER, Monks SA, Warren LL, Kaplan NL (2000) A test for linkage and genotype incompatibilities in linkage analysis. Am J Hum Genet 63: 259–266.

8. de Bakker PI, Ferreira MA, Jia X, Neale BM, Cardon LR, et al. (2007) Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum Mol Genet 17: R122–128.

9. Sullivan PF, Lin D, Tseng JY, van den Oord E, Perkins D, et al. (2008) Gene-disease association in schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 13: 570–584.

10. Howie BN, Donnelly P, Marchini J (2009) A flexible and accurate genotype imputation method for the next generation of genome-wide association studies.Nat Genet 41: 333–339.

11. Marchini J, Howie B, Myers S, McVean G, Donnelly P (2007) A new multipoint method for genome-wide association studies of quantitative traits. Nat Genet 39: 906–913.

12. North BV, Curtis D, Sham PC (2002) A note on the calculation of empirical P values from Monte Carlo procedures. Am J Hum Genet 71: 439–441.

13. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consor-tium (2011) Genome-wide association study identifies five new schizophrenia loci. Nat Genet 43: 950–955.

14. Green EK, Grozeva D, Moskvina V, Hamshere ML, Jones IR, et al. (2010) Variation at the GABRA1 receptor gene, Rho 1 (GABRA1) associated with susceptibility to bipolar schizoaffective disorder. J Med Genet 47: 67–72.

15. North BV, Curtis D, Sham PC (2002) A note on the calculation of empirical P values from Monte Carlo procedures. Am J Hum Genet 71: 439–441.

16. Zhu J, Barbujani G, Cardon LR, et al. (2005) Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum Mol Genet 17: R122–128.

17. Sullivan PF, Lin D, Tseng JY, van den Oord E, Perkins D, et al. (2008) Gene-disease association in schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 13: 570–584.

18. Howie BN, Donnelly P, Marchini J (2009) A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. Nat Genet 41: 333–339.

19. Marchini J, Howie B, Myers S, McVean G, Donnelly P (2007) A new multipoint method for genome-wide association studies of quantitative traits. Nat Genet 39: 906–913.

20. North BV, Curtis D, Sham PC (2002) A note on the calculation of empirical P values from Monte Carlo procedures. Am J Hum Genet 71: 439–441.

21. North BV, Curtis D, Sham PC (2002) A note on the calculation of empirical P values from Monte Carlo procedures. Am J Hum Genet 71: 439–441.

22. North BV, Curtis D, Sham PC (2002) A note on the calculation of empirical P values from Monte Carlo procedures. Am J Hum Genet 71: 439–441.

23. North BV, Curtis D, Sham PC (2002) A note on the calculation of empirical P values from Monte Carlo procedures. Am J Hum Genet 71: 439–441.

24. North BV, Curtis D, Sham PC (2002) A note on the calculation of empirical P values from Monte Carlo procedures. Am J Hum Genet 71: 439–441.